Catheter PrecisionVTAK
About: Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
Employees: 14
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
4.69% less ownership
Funds ownership: 9.36% [Q2] → 4.67% (-4.69%) [Q3]
29% less funds holding
Funds holding: 14 [Q2] → 10 (-4) [Q3]
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
88% less capital invested
Capital invested by funds: $415K [Q2] → $50.8K (-$364K) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for VTAK.
Financial journalist opinion
Based on 6 articles about VTAK published over the past 30 days
